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A B S T R A C T
Introduction and aim.i . Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the
safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an open-
label multicenter phase 3b trial in treatment-naive or interferon (IFN) treatment-experienced Brazilian patients with advanced hepatic
fibrosis (METAVIR F3/4) and HCV genotype (GT) 1 infection. Material and methods. All patients received coformulated OBV/
PTV/r daily + DSV twice daily (3-DAA). GT1a-infected patients received 3-DAA plus RBV for 12 weeks, except for prior pegIFN/
RBV nonresponders with cirrhosis who were treated for 24 weeks. GT1b-infected patients received 3-DAA alone (F3) or in combina-
tion with RBV (F4) for 12 weeks. The primary endpoint was sustained virologic response (HCV RNA < 15 IU/mL) at post-treatment
Week 12 (SVR12). Results. The study enrolled 222 patients, 214 achieved an SVR12 (96.4%; 95% CI, 93.1-98.2%), one GT1a-in-
fected patient experienced virologic breakthrough, six (5 GT1a) relapsed, and one was lost to follow-up. SVR12 was achieved in 111/
112 (99.1%) GT1b-infected patients, including 42/43 (97.7%) noncirrhotic, and 69/69 (100%) cirrhotic patients; and in 103/110
(93.6%) GT1a-infected patients, including 44/46 (95.7%) noncirrhotic and 59/64 (92.2%) cirrhotic patients. Overall there was a low
rate of serious adverse events (n = 6, 2.7%). One patient experienced a treatment-related serious adverse event and one patient dis-
continued treatment because of an adverse event. Discussion. The results confirm that the 3-DAA regimen with/without RBV is
well tolerated and had a favorable safety profile and is efficacious in GT1-infected patients with advanced fibrosis (METAVIR F3/4).
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INTRODUCTION
The seroprevalence of chronic hepatitis C virus (HCV)
infection in Brazil is estimated to be approximately 1.38%,
translating to currently 650,000 people who require treat-
ment, most of whom are not diagnosed.1-4 In 2017, Brazil’s
universal healthcare system updated its Guideline and
now provides free treatment for citizens with chronic
hepatitis C including individuals with HIV coinfection,
renal insufficiency, idiopathic thrombocytopenic purpura,
cryoglobulinemia, hematologic malignancies, solid organ
transplant recipients, severe extra-hepatic manifestations,
and moderate hepatic fibrosis (METAVIR stages greater
than F2 by biopsy or non-invasive methodology).5 HCV
genotype (GT) 1 is the most common across all regions of
Brazil;6 thus, a regimen must have good activity against
GT1a and GT1b to be suitable for use in this setting.
Across many regions of the world the current standard of
care for patients with chronic hepatitis C involves treatment
with combinations of orally administered direct-acting anti-
viral agents (DAAs).7-9 The combination of ombitasvir
(OBV), ritonavir-enhanced paritaprevir (PTV/r; paritapre-
vir developed by AbbVie and Enanta), and dasabuvir (DSV),
with or without weight-based ribavirin (RBV), has demon-
strated high rates of sustained virologic response at post-
treatment Week 12 (SVR12) in GT1-infected patients
without cirrhosis or with compensated cirrhosis,10-15 and is
one of several regimens recommended for this subset of pa-
tients in current treatment guidelines.7-9
The objective of this Phase 3b study was to evaluate the
efficacy and safety of 12 or 24 weeks of treatment with
OBV/PTV/r plus DSV (3-DAA) with or without RBV in
treatment-naive or interferon (IFN) treatment-experi-
enced, GT1-infected Brazilian patients with advanced he-
patic fibrosis (bridging fibrosis or compensated cirrhosis,
METAVIR F3–F4).
MATERIAL AND METHODS
TOPAZ-III (M14-225, clinicaltrials.gov identifier
NCT02442271) was a Phase 3b, open-label, multicenter tri-
al that was conducted at 16 sites in Brazil. The study con-
formed to the Declaration of Helsinki and adhered to
International Conference on Harmonization (ICH) guide-
lines. The protocol and all amendments were approved by
independent ethics committees or institutional review
boards at each study site. All patients provided written in-
formed consent prior to undergoing any study procedures.
Patients
Patients eligible for the trial were adults  18 years of
age with HCV genotype 1 infection, a serum HCV RNA
level > 1000 IU/mL at the time of screening and advanced
hepatic fibrosis. Advanced fibrosis was documented by the
results of a liver biopsy performed within 24 months prior
to receipt of the first dose of study drug (METAVIR F3,
Ishak 4, or equivalent); a liver biopsy showing cirrhosis
(METAVIR F3/4 or F4, Ishak 5 or 6, or equivalent) at any
time prior to receipt of the first dose of study drug; a Fi-
broScan® result of  9.6 kPa obtained within 6 months
prior to the first dose of study drug; or a FibroTest® result
of  0.59 obtained during the screening period. Patients
with cirrhosis could be included if they had compensated
liver disease (Child-Pugh A) with no prior history of he-
patic decompensation. Both treatment-naive and IFN-ex-
perienced patients were eligible.
Patients with cirrhosis were required to have ultra-
sound, computed tomography or magnetic resonance im-
aging within 3 months prior to screening in order to
exclude hepatocellular carcinoma.
Patients were excluded if they had a positive screening
test result for human immunodeficiency virus or hepatitis
B surface antigen. Patients were also ineligible if they had
a creatinine clearance < 30 mL/min, albumin < 2.8 g/dL,
hemoglobin < 10 g/dL, platelet count < 25 x 109/L or a to-
tal bilirubin level > 3 mg/dL. Patients who had previously
received direct acting antiviral agents were ineligible for
the trial.
Treatment
All patients received oral co-formulated OBV/PTV/r
(25/150/100 mg) once daily and DSV (250 mg twice daily)
with or without RBV (1,000 mg daily for body weight <
75 kg or 1,200 mg daily for body weight  75 kg) for 12 or
24 weeks according to HCV GT1 subtype (1a or 1b) and
METAVIR fibrosis stage (Figure 1). All noncirrhotic pa-
tients (GT1a- and GT1b-infected) and cirrhotic GT1b-in-
fected patients were assigned to 12 weeks of treatment
regardless of treatment history (naive or IFN-experi-
enced). Among GT1a-infected patients with cirrhosis,
those who were treatment naive, or who had experienced a
prior partial virologic response, breakthrough or relapse,
or who were intolerant to previous treatment with IFN-
based therapy were assigned to 12 weeks of treatment;
whereas, GT1a-infected patients with cirrhosis who had
experienced a prior nonresponse or null response to pre-
vious treatment with IFN-based therapy were assigned to
24 weeks of treatment. All GT1a-infected patients and
GT1b-infected patients with cirrhosis received RBV.
Noncirrhotic patients with GT1b infection received the
regimen without RBV.
All patients who received at least one dose of study
drug were followed up for 24 weeks after completion or
premature discontinuation of study drug.
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Figure 1. Study Design. * Treatment experienced patients with cirrhosis and GT1a infection and a prior null response or nonresponse were assigned to 24
weeks of treatment. All other patients with cirrhosis were assigned to 12 weeks of treatment. 3-DAA, ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily
+ dasabuvir 250 mg twice daily  ribavirin (weight-based). TN: treatment-naïve. TE: treatment-experienced (IFN/RBV or pegIFN/RBV experienced patients).
Efficacy and safety assessments
The primary efficacy endpoint was sustained virologic
response (the proportion of patients with HCV RNA be-
low the lower limit of quantification [LLOQ]) at 12
weeks (SVR12) after the final dose of study drug. HCV
RNA levels in plasma were determined using the CO-
BAS® AmpliPrep/COBAS® Taqman® HCV Test, v. 2.0
(LLOQ = 15 IU/mL). Secondary efficacy endpoints were
SVR12 rates by fibrosis stage, prior treatment experience
(naive, or previous IFN-based regimen), and IFN eligi-
bility (ineligible, intolerant, eligible).
Treatment-emergent adverse events (TEAEs) were
monitored from initiation of treatment until 30-days after
discontinuation of study drugs.
Resistance analyses
For any patient who experienced virologic failure,
HCV regions encoding NS3/4A, NS5A, and NS5B were
amplified by PCR and the resulting PCR products were
sequenced by population sequencing (approximately 15%
detection threshold) from the baseline sample and the
first sample obtained after virologic failure that had an
HCV RNA level  1000 IU/mL. The resulting sequences
were analyzed for the presence of pre-existing baseline
polymorphisms and treatment-emergent amino acid sub-
stitutions.
Data analyses
Given a planned enrollment of 220 patients and an esti-
mated SVR12 rate of 95%, the 2-sided 95% confidence in-
terval (CI) calculated by Wilson’s score method will be
91.3% to 97.2%. No adjustments were made for dropouts.
Analyses were performed on the intent-to-treat (ITT)
population, which consisted of all patients who received at
least one dose of study drug. Patients with missing SVR12
results were considered to be treatment failures.
Safety data were analyzed using descriptive statistics.
RESULTS
The study enrolled 222 individuals (ITT popula-
tion), including 59.9% (n = 133) with cirrhosis (48.1%
[64/133] and 51.9% [69/133] with GT1a and GT1b infec-
tion, respectively) and 40.1% (n = 89) noncirrhotic
(F3) patients (51.7% [46/89] and 48.3% [43/89] with
GT1a and GT1b infection, respectively) across 16 study
centers in Brazil. The first patient was enrolled on 27
April 2015 and the last patient completed follow-up on
26 September 2016.
The majority of patients were male (55.4%), white
(82.4%), aged < 65 years (77.0%), and had received prior
IFN-based therapy (54.1%) (Table 1). Overall, the median
age was 57 years (range 26-78), and the median BMI was
26.5 kg/m2 (range 17–51).
One cirrhotic patient who was assigned to 12 weeks of
treatment with 3-DAA plus RBV prematurely discontin-
ued study drug due to a TEAE; thus, 99.5% of patients
(221/222) completed treatment.
Efficacy
The SVR12 rate was 96.4% (214/222; 95% CI, 93.1-






TN/TE 3-DAA + RBV
F3
GT1a or b Follow-up
TN/TE 3-DAA + RBV
F4
SVR12GT1a Follow-up
TE’ 3-DAA + RBV
F4
Day 0 Week 12 Week 24 Week 36 Week 48
Pessoa MG, et al. , 2018; 17 (6): 959-968962
Table 1. Baseline demographic and clinical characteristics.
Characteristics Patients with cirrhosis (F4) Patient without cirrhosis (F3) Total
(N = 222)
GT1a GT1b GT1a GT1b
3-DAA+RBV 3-DAA+RBD 3-DAA+RBV 3-DAA
x 12 or 24 x 12 x 12 x 12
weeks weeks weeks weeks
(n = 64) (n = 69) (n = 46) (n = 43)
Male sex, n (%) 35 (54.7) 35 (50.7) 28 (60.9) 25 (58.1) 123 (55.4)
Age, years, median (range) 55.5 (29-73) 61.0 (35-78) 53.5 (26-71) 60 (34-77) 57.0 (26-78)
Ethnicity
White 53 (82.8) 56 (81.2) 40 (87.0) 34 (79.1) 183 (82.4)
Black 10 (15.6) 10 (14.5) 6 (13.0) 7 (16.3) 33 (14.9)
Other 1 (1.6) 3 (4.3) 0 2 (4.7) 6 (2.7)
BMI
< 30 47 (73.4) 53 (76.8) 37 (80.40) 32 (74.4) 169 (76.1)
 30 12 (26,6) 16 (23.2) 9 (19.6) 11 (25.6) 53 (23.9)
Host/L28B genotype, n (%)
CC 7 (10.9) 19 (27.5) 7 (15.2) 17 (39.5) 50 (55.9)
CC 40 (62.5) 35 (50.7) 29 (63.0) 20 (46.5) 124 (55.9)
TT 17 (26.6) 15 (21.7) 10 (21.7) 6 (14.0) 48 (21.6)
CrCI, mL/min, n (&)
< 50 1 (1.6) 0 1 (2.2) 0 2 (0.9)
 50 63 (98.4) 69 (100) 45 (97.8) 43 (100) 220 (99.1)
History of diabetes mellitus, n (%) 10 (15.6) 20 (29.0) 9 (19.6) 8 (16.6) 47 (21.2)
History of hypertension, n (%) 24 (37.5) 32 (46.4) 12 (26.1) 19 (42.2)) 97 (39.2)
History of depression, n (%) 6 (19.14) 9 (13.0) 6 (13.0) 3 (7.0) 24 (10.8)
Platelet count x 109/L 10 (15.6) 6 (8.7) 2 (4.3) 3 (7.0) 21 (9.5)
< 90 23 (35.9) 18 (26.1) 4 (8.7) 1 (2.3) 46 (20.7)
 90 41 (64.1) 51 (73.9) 42 (91.3) 42 (97.7) 176 (79.3)
Albumin, g/L
< 35 11 (17.2) 11 (15.9) 2 (4.3) 0 24 (10.8)
 35 53 (82.8) 58 (84.1) 44 (95.7) 43 (100) 198 (89.2)
APRI score, median (range) 2.4 (0.5-15.2) 1.8 (0.3-13.6) 1.0 (0.3-6.7) 1.0 (0.3-3.1) 1.4 (0.3-15.2)
FIB-4 score, median (range) 4.3 (1-1-14.8) 4.0 (0.9-20.8) 2.0 (0.6-9.1) 2.1 (0.5-6.1) 2.9 (0.5-20.8)
HCV RNA level, IU/mL 13 (20.3) 16 (23.2) 9 (19.6) 9 (20.9) 47 (21.2)
< 800,000 51 (79.7) 53 (76.8) 37 (80.4) 34 (79.1) 175 (78.8)
 800,000
Prior IFN treatment, n (%) 38 (59.4) 42 (60.9) 19 (41.3) 20 (46.5) 119 (53.6)
Prior treatment response, n (%)
Null response 12 (31.6) 8 (18.6) 1 (5.3) 1 (5.0) 22 (18.3)
Null response 7 (88.4) 12 (27.9) 6 (31.6) 1 (5.0) 26 (21.7)
Partial response 1 (2.6) 3 (7.0) 1 (5.3) 2 (10.0) 7 (5.8)
Relapse 8 (21.1) 14 (32.6) 4 (21.1) 8 (40.0)) 34 (28.3)
Relapse/breackthrough 4 (10.5) 2 (4.7) 4 (21.1) 2 (10.0) 12 (10.0)
IFN intolerant 1 (2.6) 1 (2.3) 1 (5.3) 4 (20.0) 7 (5.8)
Other 5 (13.2) 3 (7.0) 2 (10.5) 2 (10.0) -12 (10.0)
achieve SVR12, 1 patient experienced on-treatment viro-
logic failure, 6 patients experienced post-treatment re-
lapse and 1 GT1a-infected patient with undetectable HCV
RNA at post-treatment Week 4 was subsequently lost to
follow-up and had a missing HCV RNA value during the
SVR12 assessment window. The SVR24 rate was 95.5%
(212/222; 95% CI, 91.9-97.5%). The 2 additional patients
who did not achieve SVR24 had missing HCV RNA values
during the SVR24 assessment window (the patient with a
missing HCV RNA value during the SVR12 assessment
window also had a missing HCV RNA value during the
SVR24 assessment window). No late relapses were docu-
mented between follow-up Week 12 and follow-up Week
24, although two patients were lost to follow-up.
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The SVR12 rate was 99.1% (111/112) in patients with
GT1b infection, and 93.6% (103/110) in patients with GT1a
infection. SVR12 was achieved in 96.2% (128/133) of cir-
rhotic patients and 96.6% (86/89) of noncirrhotic patients.
Overall, 96.1% (98/102) of treatment-naive patients, and
96.7% (116/120) of patients who had received prior IFN-
based treatment achieved an SVR12 (p = not significant,
Figure 2B). Specifically, SVR12 was achieved by 97.1% in
previous relapsers, 100% in patients with previous relapse/
Table 2, Baseline characterictics of patients who experienced
virologic failure.
Characterics Patients with virologic
failure (n/N)
Male sex, n(%) 5/7 (71.4)










Platelet count x 109/L
< 90 2/7 (28.6)
 90 5/7 (71.4)
Albumin, g/L
< 35 1/7 (14.4)
 35 6/7 (85.7)
APRI score, median (range) 1.46 (0.63-4.62)
FIB-4, median (range) 3.33 (1.44-9.71)
HCV RNA level, IU/mL
< 800,00 1/7 (14.3)
 800,00 6/7 (85.7)
Prior IFN treatment, n (%) 4/7 (57.1)
Prior treatment response, n (%)
Null response 1/4 (25.0)
Relapse 2/4 (25.0)
Other 1/4 (25.0)
Figure 2. Sustained virologic response rates overall, and by HCV subtype,
hepatic fibrosis status and previous response to pegIFN/RBV combination
therapy. Definitions of responses to prior treatment with pegIFN/RBV: Re-
lapse, undetectable HCV RNA at the end of treatment, but was detected
during follow-up; Relapse/breakthrough, 1 documented result of undetect-
able HCV RNA during treatment; Nonresponse, no documented undetecta-
ble HCV RNA results during treatment, or HCV RNA was detected at the
end of treatment with insufficient data available to categorize the response
as a relapse, breakthrough, partial response or null response; Partial re-
sponse, 2-log IU/mL decrease in HCV RNA by Week 12; Null response, <
1-log IU/mL reduction in HCV RNA by Week .
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breakthrough, partial response or nonresponse, and 95.5%
in patients with a prior null response to IFN/RBV or
pegIFN/RBV combination therapy.
The baseline characteristics of the patients who experi-
enced virologic failure are presented in table 2.
Resistance-associated substitutions
in patients with virologic failure
Seven of the 8 patients who did not achieve SVR12 expe-
rienced virologic failure. Six individuals (5 infected with
GT1a, 1 with GT1b) experienced relapse during follow-
up, and 1 individual (GT1a-infected) experienced on-
treatment virologic failure (breakthrough at Week 12).
Substitutions at resistance-associated amino acid
positions in NS3, NS5A, or NS5B in patients who expe-
rienced virologic failure are shown in table 3. NS3 substi-
tutions were not detected at baseline in any patients, but
were detected at the time of virologic failure in 5 patients.
NS5A substitutions were detected in 3 patients at baseline
98 33 12 7 26 21
102 34 12 7 26 22
214 59 69 44 42
222 64 69 46 43
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and in all 7 patients at the time of virologic failure. NS5B
substitutions were detected in 2 patients at baseline and in
4 patients at the time of virologic failure. The most com-
mon treatment-emergent substitutions were R155K and
D168V in NS3, M28T and Q30R in NS5A, and C316Y,
M414I, G554D, and S556G in NS5B.
Safety
Among 222 patients in the safety population, 78.4% (174/
222) patients experienced at least 1 TEAE, and 2.7% (6/222)
patients experienced at least 1 serious AE (SAE) (Table 4).
One (0.5%) cirrhotic patient assigned to 3-DAA plus RBV
Table 3. Patients with virologic failure: NS, NS5A, and NS5B substitutions at baseline at the time of virologic failure.
Genotipe and Treatment Treatment Reason for Substitutions detected at basiline and at the time of virologic failure
cirrhosis status duratioin, virologic NS3 NS5A NS5B
status weeks failure BL VF BL VF BL VF
GT1a, cirrhotic Naïve 12 Relapse None V36M, Q80L, M28V, M28V, None M414, S556G
R155K, Q30R Q30
D168V
Experienced 12 Relapse None D168V None M28T None None
Q554D
Eperienced 24 Relapse None R155K None Q30R Y448H Y448H, G554D
Naïve 12 Breaktrough None R155K Q30H Q30R None None
Y93H
GT1a, Experienced 12 Relapse None None None Q30R None C316Y, S5556G
noncirrhotic
Naïve 12 Relapse None R155K, None Q30R None None
GT1B, Experienced 12 Relapse None None Y93H Y93H C316N C316B, M4114
noncirrhotic
Amino acid positions included in the analysis of virus from patients with GT1a infection: 36, 43, 55, 56, 80, 155, 156, 168 in NS3; 24, 28, 29, 30, 31, 32, 58,
62, 92, 93 in NS5A; 316, 414, 446, 448, 451, 553, 554, 555, 556, 558, 559, 561 in NS5B. Amino acid positions included in analysis of virus from patients with
GT1b infection: 55, 56, 155, 156, 168 in NS3; 24, 28, 29, 30, 31, 32, 58, 62, 92, 93 in NS5A; 316, 368, 411, 445, 448, 553, 556, 558, 559 in NS5B.
Table 4. Adverse events.
Patients experiencing safety 3.DAA + RBV 3-DAA 3-DAA ± RBV
events, n(%) (N = 179)* (N = 43) (N = 222)
Any TEAE 150 (83.8) 24 (55.8) 147 (78.4)
Any SAE† 5 (2.8) 1 (2.3) 6 (2.7)
SAE realted to 3-DAA treatment 1 (0.6)‡ 0 1 (0.5)
AEs leading to interruption of study drug treatment 1 (0.6) 0 1 (0.05)
AEs leading to RBV dose modification 20 (11.1 - 20 (9.0)
Incidence of individual TEAE**
Headache 42 (23.5) 6 (14.0) 48 (21.6)
Fatigue 37 (20,7) 4 (9.3) 41 (18.5)
Nausea 33 (18.4) 1 (2.3) 34 (15.3)
Pruritis 31 (17.3) 1 (2.3) 32 (14.4)
Asthenia 17 (9.5) 3 (7.0) 20 (9.0)
Diarrhea 17 (9.5) 3 (7.0) 20 (9.0)
Anemia 16 (8.9) 0 16(7.2)
Dyspepsia 14 (7.8) 1 (2.3) 15 (6.8)
Cough 13 (7.3) 1 (2.3) 14 (6.3)
Insonmia 10 (5.6) 2 (4.7) 12 (5.4)
AE: adverse event. SAE: serious AE. TEAE: treatment-emergent AE. * Includes cirrhotic and non-cirrhotic patients receiven 3-DAA + RBV for 12 weeks, and
cirrhotic patients receiving 3-DAA + RBV for 24 weeks. † SAES reported during treatment included mestastic lung adenocarcinoma, esophageal and renal
failure an transient ischemic attack in one patient. ‡ Hepatic failure. ** AEs with an incidence  5%.
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discontinued study drug treatment after Week 11 (Day 77)
because of a TEAE (Grade 2 ascites, assessed by the inves-
tigator as having no reasonable possibility of being related
to study drug), which started 5 days prior to discontinua-
tion of study drug and resolved 28 days later. This patient
achieved SVR12, but not SVR24 due to missing data, and
subsequently developed HCC and died (see description
below). TEAEs reported with an incidence  10% during
treatment included headache (21.6%), fatigue (18.5%), nau-
sea (15.3%) and pruritus (14.4%).
Six patients (2.7%) experienced SAEs during the study
(Table 4). A 65-year-old male patient with cirrhosis expe-
rienced hepatic decompensation starting at post-treatment
Day 10 that was considered to be possibly related to treat-
ment with both the 3-DAA regimen and RBV in the opin-
ion of the investigator. This patient was classified as
Child-Pugh B at screening, which was considered a pro-
tocol deviation. This patient also had a presumptive diag-
nosis of spontaneous bacterial peritonitis at this time
(aerobic and anaerobic cultures of ascitic fluid were nega-
tive), and treatment with intravenous ceftriaxone was ini-
tiated. The event of hepatic failure was considered
resolved 20 days after the last dose of study drug was ad-
ministered. Additionally, a 49-year-old male patient with-
out cirrhosis experienced renal failure and a transient
ischemic attack on treatment Day 22. Both SAEs in the lat-
ter individual were considered to be possibly related to
treatment with RBV, but not the 3-DAA regimen, in the
opinion of the investigator. All other SAEs were not relat-
ed to treatment in the opinion of the investigator.
The overall incidence of AEs and SAEs and the inci-
dence of certain AEs were numerically higher in patients
assigned to receive RBV than in patients assigned to the 3-
DAA regimen alone, although AEs were generally of mild
to moderate severity and clinically manageable (Table 4). In
particular, anemia was not reported as an AE in any patient
assigned to the RBV-free regimen, compared with 8.9% (16/
179) of patients receiving the 3-DAA regimen with RBV.
Adverse events leading to RBV dose modification (as
recommended in the RBV prescribing information) oc-
curred in 20 (9.0%) of patients. These events included ane-
mia (8 subjects), decreased hemoglobin (6 subjects), fatigue
(4 subjects), asthenia, cough (2 subjects each), and decreased
creatinine clearance, hypotension, pruritus, rash, renal fail-
ure, and respiratory tract infection (1 subject each).
Three (1.4%) deaths occurred during the post-treat-
ment follow-up period > 4 months after taking the last
dose of study drugs. One death due to HCC occurred 22
weeks post-treatment in a 54-year-old male patient with
cirrhosis who had no evidence of HCC on baseline
screening examinations; one death due to sepsis and hepat-
ic decompensation occurred 21 weeks post treatment fol-
lowing complications related to total hip arthroplasty in a
59-year-old female patient with cirrhosis; and one death
due to septicemia occurred 36 weeks post treatment in a
64-year-old male patient with diabetic vasculopathy, who
developed an Acinetobacter infection after foot trauma. None
of the three deaths were considered to be related to study
drug treatment in the opinion of the investigator.
No patients experienced a Grade 3 or greater increase
in ALT level during the study. One patient experienced a
Grade 3 decrease in hemoglobin and one patient experi-
enced a Grade 4 decrease in hemoglobin during 12 weeks
of treatment with the 3-DAA + RBV regimen.
Twelve patients (5.4%) experienced Grade 3 elevations
in total bilirubin concentration during treatment. All of
these patients had cirrhosis and were assigned to the 3-
DAA + RBV regimen. No patients experienced a Grade 4
increase in this parameter during the study.
DISCUSSION
The efficacy and safety of OBV/PTV/r + DSV (3-DAA)
with and without RBV have been demonstrated in several
previous large international phase 3 studies in patients
with GT1 infection.10-15 The present study confirms the
efficacy and safety profile of the 3-DAA regimen in Brazil-
ian patients with advanced liver fibrosis including com-
pensated cirrhosis, thrombocytopenia (platelets as low as
25,000/mm3), hypoalbuminemia (albumin as low as 2.8 g/
dL), and moderate renal dysfunction (CrCl as low as 30
ml/min). Overall, 96.4% of the patients in the ITT popula-
tion achieved an SVR12. Efficacy rates were consistently
high among GT1a-infected patients with (92.2%) and with-
out (95.7%) cirrhosis, and among GT1b-infected patients
with (100%) and without (97.7%) cirrhosis. Importantly,
only 7 out of 222 patients (3.2%) experienced virologic
failure when treated with the 3-DAA regimen. Further-
more, the 3-DAA regimen produced high response rates
regardless of previous treatment history or advanced fibro-
sis staging. These results corroborate the findings of an-
other clinical trial that explored the need for RBV among
GT1b-infected patients with cirrhosis. In the TUR-
QUOISE-III trial, 60 HCV GT1b-infected patients with
cirrhosis were treated with the 3-DAA regimen without
RBV.15 All 60 patients (100%) achieved an SVR12, indicat-
ing that RBV is not required to maximize
In resistance analyses, substitutions at resistance-associ-
ated amino acid positions in NS3, NS5A and or NS5B
were assessed at baseline and at the time of virologic fail-
ure in the seven patients (6 GT1a, 1 GT1b) who experi-
enced virologic failure. The small number of patients who
failed to achieve SVR12, and the overall pattern of resist-
ance observed in these individuals suggests that there was
no correlation between the baseline resistance profile and
the substitutions that emerged during treatment.
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Treatment with the 3-DAA regimen was well tolerated
in the present trial and the results of the safety analysis are
consistent with that reported previously in patients with
advanced hepatic fibrosis.14,15 In a population that includ-
ed only patients with advanced liver fibrosis, no new safe-
ty signals were reported during the study. One patient
discontinued treatment because of a TEAE (ascites that
evolved into a diagnosis of HCC and death), and three pa-
tients died during follow-up (>4 months after the last
dose of study drug treatment); however, none of these
events was considered to be associated with study drug
treatment. The incidence of AEs such as fatigue, nausea,
pruritus and anemia were consistently higher in patients
who received an RBV-containing regimen than in those
receiving the 3-DAA regimen alone. These AEs are likely
associated with RBV as they have previously been shown
to be reported at a higher frequency among patients rand-
omized to the 3-DAA regimen with RBV, compared to pa-
tients randomized to the 3-DAA regimen alone,11,13 and are
also associated with RBV according to the drug package
insert.16 Overall, the regimen was also well tolerated in
patients with a wide range of comorbid conditions, such as
hypertension, diabetes mellitus, depression, hypothy-
roidism, hypoalbuminemia, thrombocytopenia and mod-
erate renal dysfunction. Anemia was not reported in
patients assigned to the RBV-free regimen and the inci-
dence of anemia was < 10% in patients who received RBV.
Paritaprevir is a known inhibitor of the OAT1B1 bilirubin
transporter, which is likely responsible for the isolated
and largely asymptomatic increases in bilirubin serum lev-
els that were observed in the present study.
A notable strength of the study is the inclusion of a
large proportion of patients with advanced liver fibrosis
(F3/F4) and comorbid conditions, such as thrombocyto-
penia, and moderate renal dysfunction. It must be
emphasized however, that patients with a history of
decompensated cirrhosis were not eligible for this study,
and that the 3-DAA regimen should be avoided in
patients with decompensated cirrhosis or a previous his-
tory of decompensation. Since patients with advanced
fibrosis and a wide range of comorbidities are eligible
for treatment under Brazil’s universal health program,
the high overall efficacy and good tolerability demon-
strated in this trial could be generalized to the popula-
tion in which treatment is recommended in Brazil. The
inclusion of only patients with advanced fibrosis also
limits the generalizability of the results to a broader
population that includes patients with stage F1 and F2
fibrosis; however, other studies have focused on treatment
of patients with minimal liver fibrosis, or the full
spectrum of fibrosis stages.10-13,17
This trial has certain limitations. The open-label design
of the study is unlikely to have biased the reporting of
efficacy results because HCV RNA is an objective labora-
tory assessment; however, when combined with the lack
of control group it could have introduced bias in the re-
porting of safety events. However, the 3-DAA plus RBV
regimen was well tolerated in two placebo-controlled tri-
als in which the most common adverse events were fa-
tigue, headache, and nausea, which is consistent with the
results of the present trial.10,12
At the time the study was planned and initiated, few
DAAs were approved and available for use in Brazil. IFN-
based regimens could have been used as a comparator,
however, it would have been difficult to blind patients to
treatment with IFN-based regimens and patients may not
have been willing to accept IFN-based therapy in a com-
parative trial because of the poor tolerability and low
SVR12 rates. The study was also not powered for compari-
sons among subgroups of patients with different fibrosis
staging or prior treatment history.
In conclusion, the results of this trial confirm that
treatment with the 3-DAA regimen with RBV, or without
RBV is safe and can be an effective option for the treat-
ment of chronic HCV GT1 infection in the Brazilian pa-
tient population with bridging fibrosis or cirrhosis
(METAVIR F3/4). In particular, the 3-DAA regimen with-
out RBV is suitable for GT1b-infected patients without
cirrhosis, whereas the 3-DAA regimen with RBV is re-
quired to maximize efficacy in GT1b patients with cirrho-
sis and all GT1a patients.
ABBREVIATIONS
• AE: adverse event.
• ALT: alanine aminotransferase.
• APRI: AST to platelet ratio index.
• AST: aspartate aminotransferase.
• DAA: direct-acting antiviral agent.
• DSV: dasabuvir.
• EOT: end of treatment.
• GT1b: HCV genotype 1b.
• HCV: hepatitis C virus.
• LLOQ: lower limit of quantification.
• OBV: ombitasvir;
• PTV/r: paritaprevir coadministered with ritonavir.
• RBV: ribavirin.
• SAE: serious AE.
• SVR: sustained virologic response.
• TEAE: treatment-emergent adverse events.
• ULN: upper limit of normal.
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